VJHemOnc is committed to improving our service to you

SOHO 2020 | Standard-of-care setting results of axi-cel in R/R large B-cell lymphoma

VJHemOnc is committed to improving our service to you

Loretta Nastoupil

Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines results from the US Lymphoma CAR-T Consortium evaluating standard-of-care axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter